April 4, 2019 — Pfizer (NYSE:PFE) today announced that the U.S. Food and Drug Administration…
View More FDA Approves Ibrance (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast CancerHome »
Home »
April 4, 2019 — Pfizer (NYSE:PFE) today announced that the U.S. Food and Drug Administration…
View More FDA Approves Ibrance (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer